Summit Therapeutics Inc
SMMT
NASDAQ
Biotechnology
$13.35
USD
-0.65 (-4.64%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $11.34B
Volume 9.7M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-856.09M
TTM
-14.7%
YoY
Operating Cash Flow
$-458.43M
TTM
-121.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 360.4 | 103.1 | 77.6 | 62.6 | 62.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 568.4 | 234.2 | 224.9 | 195.2 | 220.5 |
Operating Income | -568.4 | -234.2 | -224.9 | -195.2 | -220.5 |
EBITDA | -568.4 | -234.2 | -224.9 | -195.2 | -220.5 |
Other Income / Expense | 2.5 | 2.4 | 5.8 | 5.8 | 4.8 |
Total Other Income / Expense | 2.5 | 2.4 | 5.8 | 5.8 | 4.8 |
Income Before Income Taxes | -565.9 | -231.8 | -219.2 | -189.4 | -215.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -565.7 | -231.8 | -219.2 | -189.4 | -215.7 |
Consolidated Net Income / Loss | -565.9 | -231.8 | -219.2 | -189.4 | -215.7 |
Net Income Attributable to Common Shareholders | -565.9 | -231.8 | -219.2 | -189.4 | -215.7 |
Basic EPS | -$0.76 | -$0.31 | -$0.29 | -$0.24 | -$0.28 |
Diluted EPS | -$0.76 | -$0.31 | -$0.29 | -$0.24 | -$0.28 |
Basic Shares Outstanding | 742.6M | 743.4M | 766.7M | 775.5M | 778.2M |
Diluted Shares Outstanding | 742.6M | 743.4M | 766.7M | 775.5M | 778.2M |